Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year Low – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The company traded as low as $20.40 and last traded at $20.3950, with a volume of 358,869 shares trading hands. The stock had previously closed at $20.47.

Analysts Set New Price Targets

Several research firms recently commented on GPCR. HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Weiss Ratings lowered shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Price Performance

The stock has a market cap of $1.42 billion, a P/E ratio of -20.38 and a beta of -1.12. The company has a fifty day moving average price of $32.86 and a 200 day moving average price of $49.16.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its holdings in shares of Structure Therapeutics by 36.6% in the first quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock worth $84,531,000 after acquiring an additional 469,554 shares during the period. Orbimed Advisors LLC lifted its position in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after purchasing an additional 313,600 shares during the last quarter. Janus Henderson Group PLC grew its stake in Structure Therapeutics by 5.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after buying an additional 264,833 shares in the last quarter. Siren L.L.C. increased its holdings in shares of Structure Therapeutics by 23.2% in the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock worth $64,043,000 after buying an additional 250,000 shares during the last quarter. Finally, SEB Asset Management AB bought a new position in shares of Structure Therapeutics in the 1st quarter worth $11,811,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.